All Updates

All Updates

icon
Filter
Funding
Formation Bio raises USD 372 million in Series D funding to expand clinical portfolio and advance AI drug development
Clinical Trial Technology
Jun 26, 2024
This week:
Product updates
Pimax announces compact Dream Air VR headset for USD 1,900
Extended Reality
Dec 23, 2024
Funding
HuLoop raises Series A funding from Mighty Capital
Workflow Automation Platforms
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
Financial Wellness Tools
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
FinTech Infrastructure
Dec 23, 2024
Funding
Meight raises EUR 3.4 million in funding led by Cusp Capital
Smart Mobility Information
Dec 23, 2024
Regulation/policy
Desktop Metal sues Nano Dimension over merger compliance
Additive Manufacturing
Dec 23, 2024
Management news
Nexa3D scales back operations amid financial crisis
Additive Manufacturing
Dec 23, 2024
Funding
Fraction AI raises USD 6 million in pre-seed funding to scale hybrid data labeling
Machine Learning Infrastructure
Dec 23, 2024
Last week:
Partnerships
Rocket Lab launches sixth Synspective radar satellite as part of ongoing partnership
Space Travel and Exploration Tech
Dec 21, 2024
Partnerships
EHang partners with Changan Automobile to develop eVTOL aircraft for personal transportation
Passenger eVTOL Aircraft
Dec 21, 2024
Clinical Trial Technology

Clinical Trial Technology

Jun 26, 2024

Formation Bio raises USD 372 million in Series D funding to expand clinical portfolio and advance AI drug development

Funding

  • AI-powered pharmaceutical company Formation Bio has raised USD 372 million in a Series D funding round led by Andreessen Horowitz (a16z), with participation from investors including Sanofi, Sequoia, Angel Growth, FPV Ventures, and more.

  • The proceeds will be allocated to the company’s strategies of acquiring and in-licensing clinical-stage assets from other biotech and pharma companies and enhancing its AI capabilities within drug development and clinical trials.

  • Formation Bio, formerly TrialSpark, accelerates drug development through a proprietary platform based on modern data, LLMs, AI agents, and other technology. The company acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms and leverages its AI platform to develop these assets into commercialization.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.